Classical chemotherapy for metastatic melanoma

Clinical and Experimental Dermatology

Volumn 25, Issue 6, 2000, Pages 503-508

  Becker, J C ^a,b   Kampgen E ^a   Brocker E B ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CANCER VACCINE; CARMUSTINE; CISPLATIN; CYTOTOXIC AGENT; DACARBAZINE; DOCETAXEL; FOTEMUSTINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LOMUSTINE; NITROSOUREA DERIVATIVE; PACLITAXEL; RECOMBINANT CYTOKINE; TAMOXIFEN; TAXANE DERIVATIVE; TEMOZOLOMIDE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ADOPTIVE IMMUNOTHERAPY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DOSE CALCULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNOMODULATION; LIVER METASTASIS; MELANOMA; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; UVEA MELANOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MELANOMA; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 0033774196     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2000.00690.x     Document Type: Review

References (26)

1. New approaches to the systemic treatment of melanoma
2. Adjuvant therapy of melanoma
3. Prognostic factors for survival of patients treated systemically for disseminated melanoma
4. Prognostic parameters in uveal melanoma: A review
5. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
6. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma
7. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?
8. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours
9. Phase I trial of temozolomide using an extended continuous oral schedule
10. Treatment of neoplastic meningitis with intrathecal temozolomide
11. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
12. Fotemustine in the treatment of brain primary tumors and metastases
13. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases
14. Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma
15. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma
16. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma
17. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma
18. High-dose chemotherapy and autologous stem cell support for patients with malignant melanoma
19. Immunotherapy in malignant melanoma
20. Development of a biochemotherapy regimen with concurrent administration of cisplatinl vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
21. Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors
22. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy
23. The treatment of metastatic uveal melanoma
24. BOLD + interferon in the treatment of metastatic uveal melanoma: First report of active systemic therapy
25. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - Dacarbazine and fotemustine - In patients with melanoma
26. Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature